Administration of melanotransferrin-trastuzumab conjugate (BT2111) reduced the number of HER2+ breast cancer metastases in the brain (by 68%) with tumours being 46% smaller in BT2111 treated mice relative to control mice (91). This evidence concerns the gene MELTF and neoplasm.